Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Expert Rev Mol Diagn. 2008 May;8(3):239-45. doi: 10.1586/14737159.8.3.239.

PROCLEIX West Nile virus assay based on transcription-mediated amplification.

Author information

  • 1Chiron, Novartis Vaccines & Diagnostics, Emeryville, CA, USA. rainer.ziermann@novartis.com

Abstract

The PROCLEIX West Nile virus (WNV) assay is based on transcription-mediated amplification and is the most sensitive nucleic acid test commercially available today for blood screening. Since 2003, in the USA, the assay has been used for year-round screening of blood donations in minipools of 16 and in an individual-donation testing format, when appropriate triggering guidelines for such switch become effective. The test can be run on the semiautomated PROCLEIX modular platform or the fully-automated PROCLEIX TIGRIS System. This assay and the corresponding platforms have been developed and are manufactured by San Diego-based Gen-Probe, Inc., while they are marketed and distributed by Chiron, a Novartis business. This review covers some of the epidemiological and virological aspects of WNV, as well as clinical questions and technological assessment of the transcription-mediated amplification and alternative technologies used in WNV blood screening.

PMID:
18598103
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Informa Healthcare
    Loading ...
    Write to the Help Desk